Fig. 4From: Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosisThe cost-effectiveness acceptability curves of Rituximab versus Natalizumab based on the QALY obtained through the Monte Carlo simulationBack to article page